By PPN News Staff
The FDA has approved ozanimod 0.92 mg (Zeposia, Bristol-Myers Squibb) for the treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
Bristol-Myers Squibb noted, however, that because of the COVID-19 crisis, it “has made the decision to delay commercialization” of ozanimod. The company said it made the decision “based on what’s in the